Simplify Medical said today that it plans to use its $21 million Series B round to complete a pair of pivotal studies for its namesake cervical disc replacement The round was led by Life Sciences Partners, Sunnyvale, Calif.-based Simplify said, joined by new backer Sectoral Asset Management and M.H. Carnegie, the Australian private equity shop that […]
Funding Roundup
CDC gives $12m to states to fight opioid epidemic
The Centers for Disease Control and Prevention said today that it plans to award more than $12 million this week to 23 states and the District of Columbia to support their efforts in tackling the opioid overdose epidemic. The funding comes from the fiscal year 2017 omnibus appropriations bill that became law in May. States applied for […]
OpGen prices $10m public offering
OpGen (NSDQ:OPGN) said earlier this month that it priced a $10 million public offering of 25 million units of common stock and warrants at 40¢ apiece. The molecular diagnostics company said each common warrant has an exercise price of 43¢ per share and expires five years after issuance. The offering is slated to close tomorrow. […]
AntriaBio raises $13m for injectable, once-weekly insulin
AntriaBio (OTC:ANTB) said today that it closed a $13 million private placement, supported by Aju Pharm, Ildong Pharmaceutical Co. and Medici Investment Co. According to the deal, investors paid $1.00 per share of common stock. Get the full story at our sister site, Drug Delivery Business News.
Trovagene raises $7m for precision cancer therapies
Trovagene (NSDQ:TROV) said today that it inked a deal with unnamed investors to sell approximately $7.1 million of its common stock. According to the deal, Trovagene plans to sell 6,191,500 shares of common stock. In a concurrent private placement, the biotech said it will issue warrants to buy up to 4,643,626 shares of common stock. Get […]
Ionis-spinout Akcea prices IPO below expected range
Cambridge, Mass.-based Akcea Therapeutics priced its offering of 15.6 million shares at $8 apiece to reach its $125 million IPO target. The company initially priced an offering of 9.6 million shares at $12 to $14 per share. Akcea’s shares are slated to begin trading on the Nasdaq exchange today under the “AKCA.” Get the full story at […]
Carmell Therapeutics raises $4m for regenerative biomaterial
Carnegie Mellon spin-out Carmell Therapeutics said today that it closed a $4 million Series B financing round last month that it plans to use to bring its first product candidate to Phase III clinical development. Its Bone Healing Accelerant uses pooled plasma to boost the healing of bone and soft tissues. Current investors, including Pittsburgh Life Sciences […]
5 medtech funding insights you need to know
Venture capital funding isn’t what it used to be for medical device startups, but there are actually reasons to feel optimistic about medtech funding. That was the big takeaway from a four-expert panel at DeviceTalks Minnesota last month. (The next DeviceTalks is Oct. 2 in Boston.) Charlie Whelan, director of transformational health consulting at Frost & Sullivan, […]
MobileODT raises $7m for portable cervical cancer detection device
MobileODT said today that it raised $6.8 million in a Series B financing round. OrbiMed Advisors led the financing and was joined by a previous investor, Tristel. To date, the Israeli cancer diagnostic company has raised more than $13 million. MobileODT’s device, EVA, is a cheap, portable device that uses an imaging system to detect […]
Google backs Decibel Therapeutics in big data hearing loss play
Decibel Therapeutics said today it landed an investment from GV, formerly Google Ventures. GV agreed to make an equity investment in the Boston-based company and lend its capabilities in big data sciences and analytics to Decibel’s efforts in developing therapies for hearing loss and tinnitus. Get the full story at our sister site, Drug Delivery Business […]
Delcath raises $2m in Series B stock sale
Delcath Systems (NSDQ:DCTH) has raised $2 million after selling 2,360 shares of Series B preferred stock at $1,000 per share to unnamed institutional investors, according to a regulatory filing. The company wrote that it plans to use the proceeds for general corporate purposes. Get the full story at our sister site, Drug Delivery Business News.